RT @RichardPAConway: Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucrava
Tweet Content
Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
Links
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarker…
https://acrabstracts.org/abstract/deucravacitinib-reduces-interferons-b-cell-pa…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off